FI95369C - Process for the preparation of 3-arylcarbonyl-1-aminoalkyl-1H-indole compounds with anti-glaucoma effect - Google Patents

Abstract

Antiglaucoma compositions containing 3-arylcarbonyl-1-aminoalkyl-1H-indoles, as the active component thereof, and a method of use thereof in the treatment of glaucoma. Also included are novel 3-arylcarbonyl-1-aminoalkyl-1H-indoles.

Description

1 95369

This invention relates to the preparation of novel 3-aryl-5-carbonyl-1-aminoalkyl-1H-indoles which are useful as anti-glaucoma agents.

Deschampsin et al. U.S. Patent 3,946,029 describes compounds of the following formula:

10 U

Ooc ΐ / R4

A-N

R5 15 3 wherein A is alkene; R 2 is alkyl of one to four carbons, phenyl or phenyl substituted by fluorine, chlorine, bromine, nitroxy or cyclohexyl; R 3 is a 2-, 3- or 4-pyridyl group; and R 4 and R 5 are either the same or different alkyl of 1 to 5 carbons, or R 4 and R 5 are joined together to form a piperidino, pyrrolidino or morpholino group with the nitrogen atom. The compounds are said to have fibrinolytic and anti-inflammatory activity.

.... 25 Essentially the same is disclosed in Inion et al., Eur. J. of Med. Chem. 10 (3) (1975) 276-285. In particular, these two references describe the compound 2-isopropyl-3- (3-pyridylcarbonyl) -1- [2- (4-morpholinyl) ethyl] indole.

U.S. Pat. No. 3,489,770 to Herbst generally describes: compounds of the following formula: fin0.35 i r 2 2 95369 wherein R 1 is "dialkylalkylamino, pyrrolidinyl, piperidino or morpholino and R 2 is selected from the group consisting of cyclo (lower) alkanoyl and adamantanylcarbonyl-li ". Herbst's patent also discloses a wide variety of compounds in which R 2 is an arylcarbonyl group, although these are not included in the species defined above. The compounds are said to have anti-inflammatory, antihypertensive, hypoglycemic and central nervous system effects.

10 Tambute, Acad. Sci. Comp. Rend., Ser. C, 278 (20) (1974) 1239-1242, discloses compounds of the following formula: -1 - CfiHr

I I

15 .11 N 2 (CH 2> n -N 2 O 20 where n is 2 or 3. The utility of the compounds is not reported.

U.S. Patent 4,581,354 to Bell describes 3-arylcarbonyl and 3-cycloalkylcarbonyl-1-aminoalkyl-ΙΗ-indoles which are useful as analgesics, antirheumatic drugs and anti-inflammatory agents.

The invention relates to a process for the preparation of the anti-glaucoma 3-arylcarbonyl-1-aminoalkyl-1H-indole compounds of the formula (I) and their acid addition salts, 30 ° C / CH 2 CH 7 -NO 2 2 w 3 95369 wherein: R 2 is hydrogen or lower alkyl and R 3 is lower alkoxymethylphenyl, trialkoxyalkoxyphenyl, benzyl, lower alkoxystyryl, (1H-5 imidazol-1-yl) naphthyl, 2- (1-naphthyl) ethenyl, 1- (1,2 , 3,4-tetrahydronaphthyl), anthryl, phenanthryl or pyrenyl.

Unless specifically defined otherwise, the terms lower alkyl and lower alkoxy, as used herein, mean monovalent aliphatic radicals, including branched radicals having from one to about four carbon atoms, for example, methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, methoxy, ethoxy. , propoxy, isopropoxy, butoxy and sec-butoxy.

The compounds of formula I are prepared using the methods described in claim 1. The methods are described in detail in Bell U.S. Patent 4,581,354, and many of the intermediates used in their preparation are specifically described herein.

20 In one of the methods described

In the Bell patent, compounds of formula I are prepared by reacting 2-R 2 -substituted 3-R 3 -carbonyl-1H-indole with an aminoethyl halide or aminoethyl tosylate X-Alk-N = B in the presence of an acid acceptor, wherein X is a halogen atom or a toluenesulfonyloxy group and B = N-Alk is 4-morpholininylethyl. The reaction is preferably carried out in an organic solvent inert under the reaction conditions, such as dimethylformamide (hereinafter DMF), dimethylsulfoxide (hereinafter DMSO), lower alkanol or acetonitrile. Suitable acid acceptors include an alkali metal carbonate such as sodium carbonate or potassium carbonate or an alkali metal hydride such as sodium hydride, an alkali metal amide such as sodium amide or an alkali metal hydroxide such as potassium hydroxide. Preferred solvents are DMF and DMSO, and preferred recipients of acid 95369 4 are sodium hydride, potassium carbonate and potassium hydroxide. The reaction is carried out at a temperature between about 0 ° C and the boiling point of the solvent used.

The 2-R2-substituted 3-R3-carbonyl-1H-indoles, in turn, are prepared by reacting the 2-R2-substituted indole with a lower alkyl magnesium halide and reacting the resulting Grignard compound with the appropriate R3-carboxylic acid halide. The reaction is carried out in an organic solvent inert under reaction conditions such as dimethyl ether, dioxane or tetrahydrofuran (hereinafter THF) at a temperature between -5 ° C and the boiling point of the solvent used.

In another method, compounds of formula I are prepared by reacting a 2-R 2 -substituted 1- [2- (4-morpholinyl) ethyl] -1H-indole with an appropriate R 3 -carboxylic acid halide (R 3 -C 0 -X) with a Lewis acid such as in the presence of aluminum chloride and in an organic solvent which is inert under the reaction conditions. Suitable solvents are chlorinated hydrocarbons such as methylene dichloride (hereinafter MDC) or ethylene dichloride (hereinafter EDC). The reaction is carried out at a temperature between 0 ° C and the boiling point of the solvent used.

The 2-R 2 -substituted 1-aminoalkyl-1H-indole intermediate 25 is prepared using one of two methods. In another method, a 2-R 2 -substituted indole is reacted with an amino-lower alkyl halide or amino-lower alkyl tosylate X-Alk-N = B, wherein X, Alk and N = B are as defined above, in the presence of an acid acceptor in an organic solvent inert under the reaction conditions. , using the same conditions as described above for the preparation of compounds of formula I by alkylation of a 2-R 2 -R 4 -substituted indole with an aminoalkyl halogen or tosylate.

In another method, a 2-R 2 -substituted indole is reacted with a halo-lower alkanamide X-Alk'CO-95959 N = B, wherein Alk 'is a lower alkene (CH 2) n., Where n' is an integer 1 or 2, or such a lower alkene , which is substituted with a lower alkyl group, and X and N = B have the same meaning as above. The reaction is performed in the presence of a strong 5 base, and the resulting 2-R 2 -substituted 1H-indole-1-alkanamide is then reduced with lithium aluminum-aluminum hydride. The reaction of the 2-R 2 -substituted indole with a halo-lower alkanamide is performed in a suitable organic solvent such as DMF at a temperature between -5 ° C and about 50 ° C. The reduction of the amides with lithium aluminum hydride is carried out in an inert organic solvent such as diethyl ether, THF or dioxane at a temperature between -5 ° C and about 50 ° C.

Compounds of formula I may also be prepared by reacting a 2-R 2 -substituted 3-R 3 -carbonyl-1- (tosyloxyethyl) or -1- (haloethyl) -1H-indole with an equivalent molar amount of the amine HN = B in an organic in a solvent which is inert under the reaction conditions, such as acetonitrile, lower alkanol or DMF. The reaction is preferably carried out by heating a solution of the reactants at the boiling point of the mixture.

2-R2-Substituted 3-R3-carbonyl-1- (2-tosyloxy-ethyl) - or -1- (2-haloethyl) -1H-indoles, in which Alk 25 is 1,2-ethylene, are in turn prepared by carrying out 2- Reaction of R 2 -R 4 -Substituted 3-R 3 -carbonylindole with Lower alkyllithium, for example n-butyllithium, in an inert organic solvent such as THF, dioxane or diethyl ether, followed by reaction of the resulting lithium salt with ethylene oxide. React the resulting 2-R2-substituted 3-R3-carbonyl-1- (2-hydroxy-ethyl) -1H-indole with toluenesulfonyl chloride in the presence of an acid acceptor to give 1- (2-tosyloxyethyl) -1H-indoles , while reacting the product with phosphorus trihalide gives the corresponding 1- (2-haloethyl) -1H-indoles.

2-R2-Substituted 3-R3-carbonyl-1- (haloethyl) -1H-indoles are prepared by reacting a 2-R2-substituted 3-R3-carbonylindole with a dihalo-lower alkane in the presence of a strong base such as sodium hydride in an inert organic solvent such as DMF :in. The reaction usually takes place at ambient temperature.

In another process for the preparation of compounds of formula I wherein R 3 is naphthyl substituted with an amine group, the corresponding compound of formula I wherein R 3 is halonaphthyl is reacted with a suitable amine, e.g. imidazole, in the presence of a copper (1) halide. being.

By performing further chemical treatments on the various functional groups in the compounds prepared by one or more of the methods described above, other compounds of formula I may be prepared.

The compounds of formula I in free base form are converted into the acid addition salt form by reacting the base with an acid. Similarly, the free base can be reconstituted from the acid addition salt form conventionally, i.e., by treating the salts with a cold aqueous solution of a weak base, for example, an alkali metal carbonate or alkali metal bicarbonate. Thus, the reconstituted bases can be reacted with the same or a different acid to recover the same or a different acid addition salt. The bases and all of their acid addition salts are thus readily interchangeable.

It is thus intended that Formula I not only represents the structural configuration of the bases of Formula I, but also represents the constituents common to all compounds of Formula I, whether they are in the form of a free base or in the form of acid addition salts of a base. It has been found that, because of these common constituents, the bases of formula I and their acid addition salts have a characteristic pharmacological activity of the type described in more detail below. This characteristic pharmacological activity can be utilized in a useful form for pharmaceutical purposes using the free bases or acid additions themselves. formed with pharmaceutically acceptable acids, i.e. acids whose anions are harmless to the animal body in effective doses of salts, so that the beneficial properties inherent in the common structure represented by the free bases are not negated by the side effects due to the anions.

To take advantage of this pharmacological activity of the salts of formula I, it is, of course, preferred to use pharmaceutically acceptable salts. Although some particular salt species may be unsuitable or less desirable for use as such for a particular pharmaceutical use due to their insolubility in water, high toxicity, or lack of crystalline nature, water-insoluble or toxic salts can be converted to the corresponding pharmaceutically acceptable base by water-insoluble or toxic. described or alternatively, they may be converted to any desired pharmaceutically acceptable acid addition salt by anionic double decomposition reactions, for example using ion exchange methods.

.! In addition to being useful in pharmaceutical applications, salts are useful in the characterization or identification of free bases as derivatives or in isolation or purification methods. As with all acid addition salts, these characterizing β 95369 cation or purification salt derivatives can be used, if desired, to reconstitute pharmaceutically acceptable free bases by reacting the salts with an aqueous base solution, or alternatively, they can be converted to pharmaceutically acceptable acid addition salts, for example, by ion exchange.

Acid addition salts are prepared by reacting the free base and acid in an organic solvent and isolating the salt directly or by concentrating the solution.

In standard pharmacological test methods, the compounds of formula I have been found to have cannabinoid receptor agonist activity and have thus been shown to be useful as anti-glaucoma agents.

It has been shown previously that smoking marijuana reduces intraocular pressure in humans [Helper and Frank, Marijuana Smoking and Intraocular Pressure, J. Am. Med. Assoc. 217 (1971) 1392]. The topical use or injection of delta-9-tetrahydrocannabinoin, the essential active ingredient in marijuana, throughout the body also reduces intraocular pressure [Purnell and Gregg, delta-9 Tetrahydrocannabinol, Euphoria and Intraocular Pressure in Man, Ann. Opth. 7 (1975) 921-923; Green and Pederson, Effect of delta-9 Tetrahydrocannabinol on Aqueous Dynamics and Ciliary Body Permeability in the 25 Rabbit Eye, Exptl. Eye Research 15 (1973) 499-507; Cola- "Santi, Craig and Allara, Intraocular Pressure, Ocular Toxi City and Neurotoxicity after Administration of Cannabinol or Cannibigerol, Exptl. Eye Research 39 (1984) 252-259]. Similarly, synthetic cannabinoids also reduce intraocular pressure [Green, Symunds, Oliver and Elijah, Intraocular Pressure Following Systemic Administration of Cannabinoids, Curr. Eye Research 2 (1982) 247-253, Tiedeman, Shields, Weber, Crow, Coccetto, Harris and Howes, Ophthalmology 88 (1981) 270- 277, Colasanti et al., Supra Cannabinoid receptor binding sites 9 95369 can be defined as those in which radiolabeled 4- (1,1-dimethylheptyl) -2,3'-dihydroxy-6'-alpha- (3-hydroxypropyl) - 1 ', 2', 3 ', 4', 5 ', 6'-hexahydrobi-phenyl (CP 55940) binds specifically and saturably, 5 and the binding sites are heterogeneously distributed

in the brain [Devane, Dysarz, Johnson, Melvin and Howlett, Determination and Characterization of a Cannabinoid Receptor in Rat Brain, Molecular Pharm. 34 (1988) 605-613]. Natural and synthetic cannabinoids and representative examples of the compounds of this invention bind to CP

55940 binding sites. Classification of a molecule as either an agonist or an antagonist can be made using a mouse seminal vesicle (MVD) preparation in vitro, with compounds that inhibit contractions in the MVD preparation being considered active agonists and those that do not inhibit contractions are considered antagonists. It is believed that agonist activity at the cannabinoid receptor mediates the anti-glaucoma effects of cannabinoids, and that agonist activity at this receptor correlates with intraocular pressure lowering effects in humans. Accordingly, the cannabinoid receptor agonist activity of the compounds of formula I demonstrates their utility in lowering intraocular pressure and thus in the treatment of glaucoma.

The compounds of formula I may be prepared for pharmaceutical use by combining them in unit dosage form into tablets or capsules for oral administration, either alone or in combination with suitable excipients such as calcium carbonate, starch, lactose, talc, magnesium stearate, acacia and the like. In addition, the compounds can be formulated for oral or topical administration as either aqueous solutions of water-soluble salts or aqueous solutions of alcohol, glycol or oil, or as oil-in-water emulsions in the same manner as conventional drugs.

10 95369

The percentage of active ingredient in such compositions may be varied so as to provide a suitable dosage. The dosage to be administered to a particular patient will vary at the discretion of the physician using the following criteria: route of administration, duration of treatment, patient size and health, efficacy of the active ingredient, and patient response thereto. Thus, the physician can determine the effective dosage amount of the active ingredient after considering all of the criteria and using the best judgment for the benefit of the patient.

The molecular structures of the compounds of formula I were demonstrated by their infrared, ultraviolet and NMR spectra. The structures were confirmed in the elemental analyzes by the consistency of the values calculated and obtained for the elements.

The following examples further illustrate the invention without, however, limiting it. All melting points are uncorrected.

Preparation of intermediates 20 A. 2-R, -Substituted 3-R, -carbonyl indoles

Preparation IA

To a solution of 52 ml of a solution of 3 M methylmagnesium bromide in diethyl ether at 0 ° C under a nitrogen atmosphere was added dropwise a solution of 19.0 g (0.145 mol) of 2-methylindole in 50 ml of anhydrous ether. .

When the addition was complete, the reaction mixture was stirred at room temperature for one hour, then cooled in an ice bath and treated dropwise with a solution of 34.5 g (0.15 mol) of 2,3,4-trimethoxybenzoyl chloride in anhydrous ether. The mixture was stirred at room temperature for about two! for another hour and then treated with ice water and aqueous ammonium chloride solution. The ether layer was separated, dried and evaporated to dryness to give a solid which was collected by filtration and washed with basic solvent. 11 95369 and dried to give 2-methyl-3- (2,3,4-trimethoxybenzoyl) indole.

Following a procedure similar to that described above in Preparation IA, the methyl indole and 2,3,4-trimethoxybenzoyl chloride used therein with the appropriate 2-R 2 -substituted indole and the appropriate aroyl chloride (R 3 CO-C 1) were prepared as follows. -substituted 3-arylcarbonylindoles. In some cases, the products were used directly without further purification in the next step of the synthesis of the final products of formula I and no melting points were determined. In a few cases, the weight of the products was not obtained, and thus it is not possible to calculate the yield of the products in those cases. In the tables herein and elsewhere in this patent, the melting point (° C) and recrystallization solvent of the product are given in the columns labeled "m.p. / solvent" and the percentage yield of the product is given in the columns labeled "yield".

Table A

20 Preparation R7_R3_s. p./solvent Yield 1AT CH3 2,3,4- (CH3O) 3C6H2 1AV CH39-phenanthryl 70 (dec.) / EtOH 51 1AW CH3 1-anthryl 280 (dec.) / AcOH 9 25 B. 2-R7- substituted 1-aminoalkyl-1H-indoles

(a) Alkylol 2-R 1 -substituted indole Preparation 2A

To a stirred suspension of 229.5 g (1.22 moles) of 4- (2-chloroethyl) morpholine hydrochloride 300 in 30 ml of DMSO at ambient temperature was added 200 g .1 (3.03 moles) of 85% potassium hydroxide pellets and the suspension was suspended. The mixture was stirred for 5 minutes and then treated dropwise at ambient temperature with a solution of 133.7 g (1.0 mol) of 2-methylindole in 140 ml of DMSO. The temperature of the reaction mixture rose to> 95369! during the addition of the 2-methylindole bolts and with stirring after completion of the addition. When the temperature reached 78 ° C, the mixture was cooled in a water bath until the temperature fell to 75 ° C and the mixture was stirred for a total of five three and a half hours, the temperature is decreased to ambient temperature. The mixture was then diluted with 1 liter of water and extracted with toluene. The extracts were washed with water, dried over magnesium sulfate and evaporated to dryness in vacuo and the residual dark oil was crystallized from heptane to give 224 g (92%) of 2-methyl-1- [2- (4-morpholinyl) ethyl] -1H-indole, m.p. 63-65 ° C.

Preparations 2C - 2-0

Following a procedure similar to that described above in Preparation 2A, substituting the appropriate N- (2-chloro-15-ethyl) morpholine hydrochloride and 2-methylindole for the appropriate N- (haloethyl) morpholine and the appropriate 2-R 2 -substituted indole, the following were prepared in Table B: listed 2-R2-substituted 1 - [(4-morpholinyl) ethyl] -1H-indoles.

20 Table B

Preparation R2 Alk m.p. / solvent Yield 2C H CH2CH2-46 2-O C2H5 CH2CH2 59-60 / hexane 54

Preparation of final products from 25 A. 2-R 1 -substituted 3-R 1 -carbonyl indoles

Example IA

A solution of 19 g (0.058 mol) of 2-methyl-3- (2,3,4-trimethoxybenzoyl) indole in 100 ml of DMF was reacted with 2.8 g (0.07 mol) of 50 % dispersion of sodium hydride in mineral oil in DMF and the resulting sodium salt was reacted with 10.43 g (0.07 mol) of 4- (2-chloroethyl) morpholine in DMF. The reaction mixture was poured into water to give the crude product as an oil which crystallized on standing. Recrystallization of the solid from ethyl acetate gave 13.35369 20.3 g (80%) of 2-methyl-3- (2,3,4-trimethoxybenzoyl) -1-Uz (4-morpholinyl) ethyl] -1H-indole. mp: 127-128 ° C.

Examples 1CA. 1cb. 1CF. 1CG

Following a procedure similar to that described in Example IA above, the following compounds of formula I in Table 1 were prepared by reacting 2-R 2 -substituted 3-R 3 -carbonyl-1H-indole with the appropriate haloalkylamine or tosyloxyalkylamine. The acid acceptor and reaction solvent used in the reactions are given in the column entitled "Cat / Solvent". In this and elsewhere in the tables, the form in which the product is isolated, either as the free base or the acid addition salt, is given in the columns entitled "base / salt" and the abbreviation "morph." in the column labeled N = B, 15 represents a 4-morpholinyl group. In Table 1, unless otherwise stated, the appropriate chloroalkylamine is used as the alkylating agent. In this and elsewhere in the patent and claims, alkene groups Alk are described as occurring with a 1-indolyl group attached to the carbon atom at the left end of the alkene chain and an amine group N = B attached to the carbon at the right end of the chain. 1

· \ I

95369 p

c r- M

SS- "1 w C O I h" ί S § g o -p -p ö h 1 »Tl 5 S ö" s a 8 v v3 • 2 2 ® "“ 1 1¾ · = 8 r1

B g ao «H SO

«3 β υ SS

O) s

-H fe fe W W

7i SI SS

s3 il § § 2 2 2 2

B

8 m ti tl> w <w Ο II n n b ϋ

, 3 Ä s B S S

3 * 0 pipi H m m Λ Ä

u Λ Λ N N

5 p »pi a a 3 aa o o <O O w w« "|! · · P« Pi a a. Ό «β

u O

ro ro · Η O O £ ro ro -H> i aa hm u cj> 1 -u

Il M ie tj · m -p c - ‘C 0) n -1 (C Ή ro« »Il 2 rg ro H a \» fo en n «n n aa aa

2 O O O O

•B

s

M

0) e • h · <n 2 0 <a o o o o

M H H H H

il iti t lii il lii t £ 1 in 95369 B. 2-substituted 1H-indoles

Example 2A

To a stirred, refluxing solution of 24.4 g (0.1 mol) of 2-methyl-1- [2- (4-morpholinyl) ethyl] -1H-indole in ethylene dichloride (EDC) was added 83 ml of 1.8 M a toluene solution of ethylaluminum chloride in EDC, followed by a solution of 20.02 g (0.13 mol) of phenylacetyl chloride in 400 ml of EDC. When the addition was complete, the mixture was stirred at ambient temperature for three and a half hours and then poured into 1 liter of ice with stirring and water containing an excess of potassium carbonate. The mixture was transferred to a separatory funnel, the organic layer was separated and the aqueous layer was washed with additional EDC. The combined organic extracts were then washed with water, filtered, dried over magnesium sulphate, filtered again and evaporated to dryness and the resulting crude product dissolved in isopropanol and converted to the hydrochloride salt by the addition of ether-hydrogen chloride which was recrystallized from isopropanol / methanol to give 12.1 g. %) 3-benzylcarbonyl) -1- [2- (4-morpholinyl) ethyl] -2-methyl-1H-indole hydrochloride. mp: 220-226 ° C.

Examples 2BN. 2BO. 2BP. 2BW. 2CG

Following a procedure similar to that described in Example 2Ά above, the following compounds of formula I in Table 2 below were prepared by reacting 2-R 2 -substituted 1-morpholinylethyl-1H-indole with the appropriate acid chloride (R 3 COCl) in the presence of aluminum chloride. Solvent used to carry out the reaction. methylene chloride (MDC) or ethylene dichloride (EDC) is given in the column entitled "solvent".

95369 16 o • p C φ o <5 n ° (O m ^ 10 h n <0

C/O

o a <o o O a <c i) p u 9 • h w w «p + j a h o h m o ^ 3 H _ 0 \ • h nm S in in» h I in ® oi

^ in H? rH I

. * I · I t "O oo fN co in • o m o '<n« h

10 H H H H

, 2h to n sT to S 0 Μ Λ rj cn: g ^ g § f * ^ §

rH

o s c

•B

P

3 oy y o y 3 g S S § 8 n

O (H <«- l« w «H <M

2 «U P P

• g H o o o o o

5 Ä fi S fi β B

3 <0 n H m j * J * n g, ¾ <N ΙΊ wf ^ <s δ δ g δ «'! ! ! ! ! • Η ιΗ • H I £ ’H Ä fr

Sm -H P

C H <W a

M> 1 JS * o * H

>, K? o H

ι) P I IN> 1 g C -h a x>, I (C -H I u c o c £> 1 «O 0) s" h c £ »" S, O w 0) 0) O Q4

n I I +> »* I

N β y ^ N

rH

n «n Jp fo 05 * S O K o u

•B

ä

M

0) e

• H OO A Ä O

10 CQ CQ (Q CQ U

H NM N N N

il '9H i g It! I I f * »1 17 95369 C. Miscellaneous methods

Example 3A

A mixture of 0.02 moles of 3- (4-bromo-1-naphthylcarbonyl) -2-methyl-1- [2- (4-morpholinyl) ethyl-1H-5 indole and 0.48 moles of copper (1 ) bromide and imidazole in DMF containing pyridine were heated at reflux for eight hours and then the mixture was poured into 10% ammonium hydroxide. The separated solid was collected by filtration, dissolved in MDC, and the solution 10 was passed through a silica gel column. The eluate was diluted with ethyl acetate and the solid which separated on standing was collected and dried to give 0.5 g of 2-methyl-3- [1- [4- (1-imidazolyl) naphthyl] carbonyl] -1- [2 - (4-morpholinyl) ethyl] -1H-indole, m.p. 173.5 15-177 ° C.

Example 3B

Following a procedure similar to that described in Example 3A above, 3- (4-bromo-1-naphthylcarbonyl) -1- [2- (4-morpholinyl) ethyl] -1H-indole was reacted with 20 equivalent molar amounts of copper (1) bromide and imidazole in DMF in the presence of a molar excess of potassium carbonate to give 78.0 g of the corresponding 3- [1- [4- (1-imidazolyl) naphthyl] carbonyl] -1- [2- (4-morpholinyl) ethyl] - 1H-indole isolated in free ... 25 base form, m.p. 198-200 ° C.

Results of biological tests

Data from the mouse seminal vesicle test (MVD) and CP55490 binding assay (CP), expressed as IC50, μΜ, for the compounds described above, identified by the number of the example in which their preparation is described, are given in the table below. 5. Compounds are considered active in the MVD test at IC50 levels of 5.0 μΜ or lower.

18 95369

Table 5

Example MYD £ E

IA 0.1 59% Ι / 1μΜ 1CA 0.07 70% Ι / 1μΜ 5 1CB 0.09 1CF 0.06 1CG 0.17 2BN 0.138 2BO 0.13 10 2BP 0.01 2BW 0.9 2CG 0.04 3A 0.008 3B 0.005 15

Claims (3)

19 95369 A process for the preparation of 3-arylcarbonyl-1-aminoalkyl-1H-indole compounds of formula (I) of formula (I) and their acid addition salts, 0 N x 1 R 2 CH 9 CH 0 -N 0, W wherein: R 2 is hydrogen or lower alkyl and R3 is lower alkoxymethylphenyl, trialempkoxyphenyl, benzyl, lower alkoxystyryl, (1H-imidazol-1-yl) naphthyl, 2- (1-naphthyl) ethenyl, 1- (1,2,3,4-tetrahydronaphthyl), anthryl , phenanthryl or pyrenyl; characterized in that: (a) 2-R 2-3-R 3 -carbonyl-1H-indole is reacted with a compound of formula X-Alk-N = B in the presence of an acid acceptor in an organic solvent, wherein X is a halogen atom or a toluenesulfonyloxy group. m, B = N-Alk is 4-morpholininylethyl and R 2 and R 3 are as defined above; (b) reacting 2-R 2-1- [2- (4-morpholinyl) ethyl] -1H-indole with an R 3 carboxylic acid halide of formula R 3 -C 0 -X in the presence of a Lewis acid in an organic solvent, wherein X is a halogen atom and R 2 and R 3 are as defined above; or ·: (c) administering 3- (4-halo-1-naphthylcarbonyl) - Process according to Claim 1, characterized in that 3- [1- (1,2,3,4-tetrahydronaphthyl) carbonyl] -1- [2- (4-morpholinyl) ethyl] -1H-indole is prepared . To react 2-R 2-1- [2- (4-morpholinyl) ethyl] -1H-indole with imidazole in the presence of a copper (1) halide in an organic solvent, wherein R 2 has the meaning given above to give the formula A compound of formula I wherein R 3 is (1H-imidazol-1-yl) naphthyl, 95369 and, if desired, converting the resulting free base to the corresponding acid addition salt. Process according to Claim 1, characterized in that 3-benzylcarbonyl-2-methyl-1- [2- (4-morpholinyl) ethyl] -1H-indole is prepared. «Si> sat iki; i i j m; 21 95369